What is Osimertinib?
Category: Prescription Drugs
Most popular types: Tagrisso
Osimertinib is a treatment for non-small cell lung cancer.
| Purpose | Patients | Evaluations | Perceived Effectiveness |
|---|---|---|---|
| Adenocarcinoma (non-small cell lung cancer) | 51 | 7 | |
| Non-small cell lung cancer | 10 | 0 | |
| Squamous cell carcinoma (non-small cell lung cancer) | 4 | 0 | |
| Adenosquamous carcinoma (non-small cell lung cancer) | 3 | 1 | |
| Lung cancer | 2 | 0 |
- Major
- Moderate
- Slight
- None
- Can't tell
Side effects
Side effects as an overall problem
| Severity | Evaluations | Percentage |
|---|---|---|
| Severe | 0 | |
| Moderate | 3 | |
| Mild | 4 | |
| None | 0 |
Commonly reported side effects and conditions associated with Osimertinib
| Side effect | Patients | Percentage |
|---|---|---|
| Diarrhea | 2 | |
| Brittle hair | 1 | |
| Brittle nails | 1 | |
| Broken nails | 1 | |
| Chronic fatigue | 1 | |
| Decreased appetite | 1 |
Why patients stopped taking Osimertinib
Multiple reasons could be selected
| Reason | Patients | Percentage |
|---|---|---|
| Did not seem to work | 2 | |
| Doctor's advice | 2 |
Duration
Stopped taking Osimertinib
| Duration | Patients | Percentage |
|---|---|---|
| 1 - 6 months | 1 | |
| 1 - 2 years | 1 |
What people switch to and from
Patients started taking Osimertinib after stopping:
| Treatment | Patients | Percentage |
|---|---|---|
| Erlotinib (Tarceva) | 8 | |
| Chemotherapy | 5 | |
| Afatinib (Gilotrif) | 3 | |
| Gefitinib (Iressa) | 3 | |
| Pembrolizumab (Keytruda) | 1 |
Patients stopped taking Osimertinib and switched to:
| Treatment | Patients | Percentage |
|---|---|---|
| Chemotherapy | 2 | |
| Atezolizumab (Tecentriq) | 1 | |
| Pembrolizumab (Keytruda) | 1 | |
| Pemetrexed-carboplatin chemotherapy | 1 |
Last updated: